F. Datko

发表

The HIT Expert Probability (HEP) Score: a novel pre‐test probability model for heparin‐induced thrombocytopenia based on broad expert opinion

T. Ortel, K. Propert, D. Cines, 2010, Journal of thrombosis and haemostasis : JTH.

Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).

M. Berger, S. Chandarlapaty, D. Lake, 2014 .

Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

M. Berger, S. Chandarlapaty, D. Lake, 2015 .

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

M. Dickler, F. Datko, 2012 .

Targeted therapies: EGFR inhibitors

M. Dickler, F. Datko, 2011 .